Literature DB >> 16389002

Unresectable hepatocellular carcinoma: survival and prognostic factors after lipiodol chemoembolisation in 89 patients.

J Dumortier1, F Chapuis, O Borson, B Davril, J-Y Scoazec, G Poncet, L Henry, O Boillot, F Mion, F Berger, C Partensky, P Paliard, P-J Valette.   

Abstract

BACKGROUND: The majority of patients with hepatocellular carcinoma are not eligible for surgical radical treatment (resection or liver transplantation) and lipiodol chemoembolisation is an efficient alternative procedure in this indication. AIMS: To identify prognostic factors in patients treated with lipiodol chemoembolisation. PATIENTS AND METHODS: During 10 years, 89 consecutive patients with unresectable hepatocellular carcinoma underwent lipiodol chemoembolisation as a single treatment. There were 80 males and 9 females, with a median age of 65 years. Treatment consisted of one to six courses of hepatic intra-arterial lipiodol with doxorubicine and gelatin sponge.
RESULTS: The median survival was 13 months with a 13.6% survival rate at 4 years. Univariate analysis showed that serum levels of albumin, bilirubin, alkaline phosphatase and alpha-fetoprotein, Child's class, tumour type, tumour size and intensity of lipiodol capture after the first course of lipiodol chemoembolisation were significant prognostic factors of survival. In the multivariate analysis, four parameters remained associated with a significantly better outcome: Child's class A, largest lesion<5 cm, uninodular tumour and intense lipiodol capture.
CONCLUSIONS: While lipiodol chemoembolisation is associated with good results only in some patients, in the absence of lipiodol capture, it should be ruled out.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16389002     DOI: 10.1016/j.dld.2005.10.025

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  11 in total

Review 1.  Transcatheter embolization therapy in liver cancer: an update of clinical evidences.

Authors:  Yì-Xiáng J Wáng; Thierry De Baere; Jean-Marc Idée; Sébastien Ballet
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

Review 2.  Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system?

Authors:  Xavier Adhoute; Guillaume Penaranda; Paul Castellani; Herve Perrier; Marc Bourliere
Journal:  World J Hepatol       Date:  2015-03-27

3.  Theranostics and contrast-agents for medical imaging: a pharmaceutical company viewpoint.

Authors:  Jean-Marc Idée; Stéphanie Louguet; Sébastien Ballet; Claire Corot
Journal:  Quant Imaging Med Surg       Date:  2013-12

Review 4.  Therapy of Intermediate-Stage Hepatocellular Carcinoma: Current Evidence and Clinical Practice.

Authors:  Nathan X Chai; Julius Chapiro
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

5.  Other non-surgical treatments for liver cancer.

Authors:  Paul Revel-Mouroz; Philippe Otal; Marion Jaffro; Antoine Petermann; Olivier Meyrignac; Pierre Rabinel; Fatima-Zohra Mokrane
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-14

6.  Comparison of survival rates between patients treated with transcatheter arterial chemoembolization and hepatic resection for solitary hepatocellular carcinoma.

Authors:  Yasutaka Baba; Sadao Hayashi; Kazuto Ueno; Masayuki Nakajo; Shinichi Ueno; Fumitake Kubo; Yoshirou Baba; Masahiro Hamanoue; Susumu Hasegawa; Hirohito Tsubouchi; Yasuji Komorizono
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

Review 7.  Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients.

Authors:  Antonio Facciorusso; Raffaele Licinio; Nicola Muscatiello; Alfredo Di Leo; Michele Barone
Journal:  World J Hepatol       Date:  2015-08-08

8.  A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer.

Authors:  L Kadalayil; R Benini; L Pallan; J O'Beirne; L Marelli; D Yu; A Hackshaw; R Fox; P Johnson; A K Burroughs; D H Palmer; T Meyer
Journal:  Ann Oncol       Date:  2013-07-14       Impact factor: 32.976

9.  Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study.

Authors:  Tatjana Gruber-Rouh; Cornelia Schmitt; Nagy N N Naguib; N A Nour-Eldin; Katrin Eichler; Martin Beeres; Thomas J Vogl
Journal:  BMC Cancer       Date:  2018-02-14       Impact factor: 4.430

10.  A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization.

Authors:  Sadahisa Ogasawara; Tetsuhiro Chiba; Yoshihiko Ooka; Naoya Kanogawa; Tenyu Motoyama; Eiichiro Suzuki; Akinobu Tawada; Ryosaku Azemoto; Masami Shinozaki; Masaharu Yoshikawa; Osamu Yokosuka
Journal:  PLoS One       Date:  2015-04-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.